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Abstract
Introduction: Although prompt initiation of appropriate antifungal therapy is essential for the control of invasive
Candida infections and an improvement of prognosis, early diagnosis of invasive candidiasis remains a challenge
and criteria for starting empirical antifungal therapy in ICU patients are poorly defined. Some scoring systems, such
as the “Candida score” could help physicians to differentiate patients who could benefit from early antifungal
treatment from those for whom invasive candidiasis is highly improbable. This study evaluated the performance of
this score in a cohort of critically ill patients.
Methods: A prospective, observational, multicenter, cohort study was conducted from January 2010 to March 2011
in five intensive care units in Nord-Pas de Calais, an area from North of France. All patients exhibiting, on ICU
admission or during their ICU stay, a hospital-acquired severe sepsis or septic shock could be included in this
study. The data collected included patient characteristics on ICU admission and at the onset of severe sepsis or
septic shock. The “Candida score” was calculated at the onset of sepsis or shock. The incidence of invasive
candidiasis was determined and its relationship with the value of the “Candida score” was studied.
Results: Ninety-four patients were studied. When severe sepsis or shock occurred, 44 patients had a score = 2, 29
patients had a score = 3, 17 patients had a score = 4, and 4 patients had a score = 5. Invasive candidiasis was
observed in five (5.3%) patients. One patient had candidemia, three patients had peritonitis, and one patient had
pleural infection. The rates of invasive candidiasis was 0% in patients with score = 2 or 3, 17.6% in patients with
score = 4, and 50% in patients with score = 5 (p < 0.0001).
Conclusions: Our results confirm that the “Candida score” is an interesting tool to differentiate among ICU patients
who exhibit hospital-acquired severe sepsis or septic shock those would benefit from early antifungal treatment
(score > 3) from those for whom invasive candidiasis is highly improbable (score ≤ 3).
Introduction
Invasive Candida infections are the most common inva-
sive fungal infections, accounting for 70-90% of all inva-
sive mycoses [1]. Among the causes of nosocomial
bloodstream infections, Candida ranks number four in
the United States [2]. Incidence of candidemia varies
between 0.5 and 1.4 per 10,000 patient-days in hospital
and between 2 and 6.9 per 1,000 admissions in the
intensive care unit (ICU) [3-7]. Invasive candidiasis is
associated with high mortality, especially in ICUs [8-10].
Prompt initiation of appropriate antifungal therapy is
essential for the control of invasive Candida infections
and has been shown to reduce mortality [11-13].
Unfortunately, early diagnosis of invasive candidiasis
remains a challenge, and criteria for starting empirical
antifungal therapy in ICU patients are poorly defined.
Recent IDSA guidelines suggest that “empirical antifungal
therapy should be considered in critically ill patients with
risk factors for invasive candidiasis and no other known
cause of fever” [14]. Risk factors for invasive candidiasis
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provided the original work is properly cited.are well identified [15]. However, these are so numerous
that most ICU patients could be considered as exhibiting
risk factors for invasive candidiasis. Obviously, widespread
use of antifungal agents would be associated with substan-
tially increased overall health care costs and emergence of
resistance [16,17].
To both ensure appropriate and timely antifungal ther-
apy and to avoid unnecessary use of antifungal agents,
some authors have developed clinical prediction rules to
identify ICU patients at high risk of candidiasis and for
whom initiation of empirical antifungal therapy could be
justified [18-20]. However, there are many concerns
about these rules: high specificity but low sensitivity, no
prospective validation, and complicated use.
In 2006, a Spanish group, using the database of the Estu-
dio de Prevalencia de CANdidiasis project, identified four
predictors of proven invasive Candida infection [21].
Based on these predictors, a score named “Candida score”
was built. In 2009, the same group demonstrated a signifi-
cant linear association between increasing values of the
“Candida score” and the rate of invasive Candida infec-
tions [22]. Such a score could be useful to stratify the risk
of proven Candida infection and differentiate patients
who would benefit from early antifungal treatment from
those for whom invasive candidiasis is highly improbable.
The goal of the present study was to evaluate, in a pro-
spective and multicenter cohort of ICU patients develop-
ing hospital-acquired severe sepsis or septic shock, the
performance of the “Candida score.”
Materials and methods
Study population
This prospective observational cohort study was per-
formed from January 2010 to March 2011 in five ICUs
(Lens, Lille, Maubeuge, Roubaix, and Tourcoing) in
Nord-Pas de Calais, an area from the north of France.
The study protocol was submitted to the Institutional
Review Board for Lille University Hospital, which gave an
approval with waiver of informed consent, in agreement
with French regulations concerning observational studies
that do not modify existing diagnosis or therapeutic
strategies.
All patients exhibiting, on ICU admission or during their
ICU stay, hospital-acquired severe sepsis or septic shock
could be included in this study. Exclusion criteria were
community-acquired infections, age < 18 years, neutrope-
nia defined as a total leukocyte count < 500/mm
3,p r e g -
nant women and nursing mothers, and patients who were
treated with antifungal drugs when severe sepsis or septic
shock occurred.
Study design
The primary objective of this study was to determine the
incidence of invasive candidiasis among included patients
and to study the relationship between the presence of
invasive candidiasis and the “Candida score” value at the
onset of severe sepsis or septic shock. The secondary
objective was to analyze the antifungal therapies insti-
tuted when severe sepsis or shock occurred and to deter-
mine their relationship with the “Candida score” value.
Data collection, evaluation, and definition
On ICU admission, demographic characteristics, underly-
ing diseases, reason for ICU admission, and severity of ill-
ness were recorded by each investigator on a standardized
report form. Underlying diseases included insulin-depen-
dent diabetes mellitus, neurologic conditions, chronic
obstructive pulmonary disease, chronic liver disease,
chronic renal failure, congestive severe heart failure, and
immunosuppression (prednisolone >0.5 mg/kg/d since
more than 1 month, human immunodeficiency virus infec-
tion, cancer chemotherapy within the past 3 months,
organ transplantation with ongoing immunosuppressant,
bone marrow allograft or hematopoietic stem-cell trans-
plantation, immunosuppressant, or anti-tumor necrosis
factor).
According to diagnoses at the time of ICU admission,
patients were classified as surgical (admission for the post-
operative care of an elective or urgent surgical procedure),
trauma (admission because of trauma-related acute
lesions), or medical (all other patients). Severity of illness
on admission in ICU was assessed by using the Simplified
Acute Physiology Score (SAPS) II and the Sepsis-related
Organ Failure Assessment (SOFA) score [23,24].
During the ICU stay, screening for Candida coloniza-
tion was performed twice weekly by routine samples
from tracheal aspirates and urine. Other samples from
peripheral blood, vascular catheters, wound or drainage
exudates, or other infected foci could be obtained at the
discretion of the attending physician. Samples were pro-
cessed by the different clinical microbiology laboratories
of the participating hospitals.
When hospital-acquired severe sepsis or septic shock
occurred, components of the “Candida score” and thera-
peutic data were collected. Severe sepsis and septic shock
were defined according to international sepsis definition
[25]. They were considered as hospital-acquired when
infection was neither present nor incubating at the time
of admission to the acute care setting [26]. Components
of “Candida score” were severe sepsis, total parenteral
nutrition, surgery, and multifocal Candida colonization.
These components were defined according to criteria
proposed by Leon et al. [21]. The “Candida score” was
calculated by adding points provided by each component
as proposed by Leon et al. in their second study [22]. In
our cohort, the minimum value of the score was 2 points
for all patients, because severe sepsis or septic shock
were inclusion criteria. The total score was obtained by
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eral nutrition, surgery, and multifocal Candida coloniza-
tion. Candida colonization was considered multifocal
when Candida species were isolated, at the same
moment, from two or more noncontiguous foci, even if
Candida species were different. In some patients, data
about Candida colonization were unknown when severe
sepsis or septic shock occurred (i.e., patients admitted in
ICU from another ward or another hospital). Samples
from tracheal aspirates or urine were obtained at admis-
sion and the final Candida score was only determined
when cultures results were available. Finally, the decision
to treat a patient with antifungal drugs during the course
of this observational study was at the discretion of each
attending physician. In all cases, the date of starting anti-
fungal treatment and antifungal agents administered
were recorded.
In all patients, usual risk factors for invasive Candida
infection, not included in the “Candida score,” such as
exposition to invasive devices (endotracheal tube for
mechanical ventilation, central venous catheter, implan-
table drug delivery system, urinary catheter), antibiotic
therapy for more than 5 days within the past 2 weeks,
immunosuppression, renal failure, and insulin-depen-
dent diabetes mellitus were recorded.
Invasive candidiasis was defined according to usual cri-
teria, such as those proposed by Leon et al. [21,22]. Briefly,
candidemia was defined by at least one positive blood cul-
ture, and peritonitis was diagnosed on the basis of macro-
scopic findings and direct examination or positive culture
for Candida of the peritoneal fluid collected during surgi-
cal procedure. Isolation of Candida species from normally
sterile body fluids, such as pleural or pericardial fluid, also
was considered as definite criteria of invasive candidiasis.
Patient mortality at the time of ICU discharge was
determined.
Statistics
Variables were expressed as median values and ranges for
numerical variables and as frequencies and percentages for
categorical variables. Categorical variables were compared
using the Chi-square and Fisher’s exact tests. Numerical
variables were compared using parametric test (Student’s
test) or nonparametric tests (Wilcoxson, Kruskal-Wallis)
according to the sample size of the groups, the number of
groups, and the normality of parameters. Statistical signifi-
cance was accepted at the 5% level.
Results
Ninety-four patients were included. Main patients’ char-
acteristics on ICU admission are summarized in Table 1.
At inclusion, 73 patients exhibited septic shock and 21
had severe sepsis. The median time between ICU
admission and occurrence of shock or severe sepsis was 7
(range, −1 to 37) days. Mean SOFA score was 9.9 ± 2.12.
When severe sepsis or shock occurred, 27 patients had
a total parenteral nutrition, 31 had undergone a surgical
procedure immediately before or during ICU stay, and
17 had a multifocal Candida colonization. Candida spe-
cies were found in urine (n = 17) and tracheal aspirates
(n = 17) cultures. Thirty-seven Candida isolates were
identified: C. albicans (n = 30), C. tropicalis (n = 3),
C. parapsilosis (n = 2), and other species (n = 2). Calcu-
lated and distribution of “Candida scores” w a sa sf o l -
lows: 44 patients with no risk factor had a score = 2; 29
patients with a lone risk factor (total parenteral nutrition
n = 8, surgery n = 10, and multifocal Candida coloniza-
tion n = 11) had a score = 3; 17 patients with two risk
factors (total parenteral nutrition n = 15, surgery n =
17, and multifocal Candida c o l o n i z a t i o nn=2 )h a da
score = 4. Finally, four patients had all risk factors and a
score = 5.
Numerous other risk factors for invasive Candida
infection were present and are reported in Table 2, bro-
ken by “Candida score” value. Among the 94 patients,
severe sepsis or septic shock were due to or associated
with invasive candidiasis in 5 (5.3%) patients. One
patient had C. parapsilosis candidemia, three patients
had C. albicans peritonitis, and one patient had C. tropi-
calis pleural infection. The patient with C. parapsilosis
candidemia had C. albicans-positive tracheal aspirates
cultures and C. parapsilosis-positive urine cultures.
Among the three patients with peritonitis, only one had
multifocal Candida colonization with C. albicans-posi-
tive tracheal aspirates and urine cultures. The patient
Table 1 Main patients’ characteristics on ICU admission
Characteristics
Mean age, yr (±SD) 62.8 (±9.9)
Male/female ratio 71/23
Mean SAPS (±SD) 51.1 (±2.12)
Mean SOFA score (±SD) 8.32 (±1.12)
Diagnosis on ICU admission, no. (%)
Medical 68 (72.3)
Surgical
Abdominal surgery
25 (26.6)
16 (17)
Trauma 1 (1.1)
Underlying diseases, no. (%)
Congestive severe heart failure 15 (16)
Insulin-dependent diabetes mellitus 11 (11.7)
Chronic obstructive pulmonary disease 26 (27.7)
Chronic liver disease 12 (12.8)
Chronic neurologic disease 10 (10.6)
Chronic renal failure 11 (11.7)
Immunosuppression 9 (9.6)
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tive tracheal aspirates and urine cultures.
The rates of invasive candidiasis according to the
“Candida score” was 0% in the 44 patients with score =
2 and the 29 patients with score = 3, 17.6% (n = 3) in
the 17 patients with score = 4, and 50% (n = 2) in the 4
patients with score = 5. The association between
increasing values of the “Candida score” and the rate of
invasive candidiasis is statistically significant (p <
0.0001). In patients with a “Candida score” ≤3, no inva-
sive candidiasis was observed. The positive and negative
predictive values of this cutoff value of the “Candida
score” were 23.8% and 100%, respectively. Among the
68 patients with medical diagnosis on ICU admission, 4
had a “Candida score” >3 and 1 of 4 exhibited an inva-
sive candidiasis. Among the 25 patients with a surgical
diagnosis on ICU admission, 17 had a “Candida score”
>3 and 4 of 17 had an invasive candidiasis. Although
the number of patients with a “Candida score” >3 was
higher in surgical than medical patients (p < 0.0001),
the rate of invasive candidiasis was similar for surgical
and medical patients with a “Candida score” >3 (4/17
vs. 1/4; p = 1). When severe sepsis or septic shock
occurred, 19 (20%) patients received empiric antifungal
treatment with fluconazole in 12 cases and caspofungin
in 7 cases. Empiric antifungal treatment was initiated in
1 of 44 (2.3%) patients with a “Candida score” =2 ,8o f
29 (27.6%) patients with a “Candida score” =3 ,7o f1 7
(41.2%) patients with a “Candida score” =4 ,a n d3o f4
(75%) patients with a “Candida score” =5 .A l lf i v e
patients with invasive candidiasis received, when severe
sepsis or septic shock occurred, empirical antifungal
therapy.
Forty-six (49%) patients died during their ICU stay.
Among the 68 patients with a medical diagnosis on ICU
admission, 32 (47%) died, whereas among the 25 patients
with a surgical diagnosis on ICU admission, 14 (56%)
died (p = 0.45). Mortality rates according to the values of
the “Candida score” and the empiric initiation of antifun-
gal treatment are reported in Table 3. No statistically sig-
nificant difference was observed. Among the 73 patients
with a “Candida score” ≤3, 33 (45%) died, whereas
among the 21 patients with a score >3, 13 (62%) died (p
= 0.17). An empiric antifungal treatment was instituted
in 19 patients, and 10 (53%) of them died. Thirty-six
(48%) of the 75 patients who did not receive empiric anti-
fungal treatment died. Such a difference was not statisti-
cally significant (p = 0.72). Finally, among the 21 patients
with a “Candida score” >3, mortality was not different
for patients who received or did not receive empiric anti-
fungal treatment (6/10 vs. 7/11; p = 1).
Discussion
This prospective cohort study confirms that the “Candida
score” is an interesting tool to differentiate, among ICU
patients with hospital-acquired severe sepsis or septic
shock, those who would benefit from early antifungal
treatment (score > 3) from those for whom invasive candi-
diasis is highly improbable (score ≤ 3).
For patients who develop, during ICU stay, severe sep-
sis or septic shock, it has been demonstrated a few dec-
ades ago that prompt and adequate antimicrobial
treatment is associated with prognosis improvement.
Moreover, it was demonstrated that bloodstream infec-
tions due to Candida species were independently asso-
ciated with administration of inadequate antimicrobial
treatment [27]. These results led physicians to question
the interest of adding an antifungal agent to the empiri-
cal antibiotic regimen administered to patients with
severe sepsis or septic shock. However, criteria for start-
ing empirical antifungal therapy in ICU patients are
poorly defined and recent IDSA guidelines suggesting
that “empirical antifungal therapy should be considered
in critically ill patients with risk factors for invasive can-
didiasis and no other known cause of fever” could lead
to an overuse of antifungal agents. The “Candida score”
Table 2 Risk factors for invasive candidiasis, according to the value of “Candida score”
Risk factors Candida score = 2
(n = 44)
Candida score = 3
(n = 29)
Candida score = 4
(n = 17)
Candida score = 5
(n = 4)
Severe sepsis or septic shock 44 29 17 4
Total parenteral nutrition 0 8 15 4
Surgery 0 10 17 4
Multifocal Candida colonization 0 11 2 4
Invasive mechanical ventilation 30 23 11 2
Central venous catheter 39 27 15 4
Urinary catheter 42 27 17 4
Antibiotherapy > 5 days within the past 2 weeks 39 25 14 4
Renal replacement therapy 8 10 4 1
Insulin-dependent diabetes mellitus 7 4 0 0
Immunosuppression 4 3 2 0
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ciated with increased health costs and development of
resistance, and underuse, associated with prognosis
impairment of critically ill patients.
In 2006, Leon et al. reported a prospective, cohort,
observational, multicenter study of 1,669 adult ICU
patients admitted to 73 medical-surgical Spanish ICUs
between May 1998 and January 1999 [21]. They identi-
fied four independent factors associated with a greater
risk for proven invasive Candida infection. A bedside
scoring system called “Candida score” was built as fol-
lows: Candida score = 0.908 × (total parenteral nutri-
tion) + 0.997 × (surgery) + 1.112 × (multifocal Candida
species colonization) + 2.038 × (severe sepsis). All vari-
ables were coded 1 if present and 0 if absent. According
to receiver operating characteristics (ROC) curve and
area under the ROC curve, a score > 2.5 accurately
identified patients with the greater risk of proven inva-
sive Candida infection (sensitivity 81%, specificity 74%).
In 2009, Leon et al. prospectively studied 1,107 adult
ICU patients admitted between April 2006 and June
2007 in 36 medical-surgical ICU in Spain, France, and
Argentina [22]. They used a rounded “Candida score”
calculated as follows (all variables were coded 0 if absent
and 1 if present): 1 × (total parenteral nutrition) + 1 ×
(surgery) + 1 × (multifocal Candida colonization) + 2 ×
(severe sepsis). They demonstrated a linear and signifi-
cant association between increasing values of the “Can-
dida score” and the rate of invasive candidiasis. The
incidence rate was 2.3, 8.5, 16.8, and 23.6 when the
s c o r ew a s< 3 ,3 ,4 ,a n d5 ,r e s p e c t i v e l y .T h e yc o n c l u d e d
that invasive candidiasis is highly improbable in patients
with “Candida score” <3.
Our results are in accordance with Leon’s data. The
incidence rates of invasive candidiasis were 0%, 0%,
17.6%, and 50% in patients with scores equal to 2, 3, 4,
and 5, respectively. A linear and significant association
between increasing values of the “Candida score” and
the rate of invasive candidiasis was observed, and no
invasive candidiasis occurred in patients with scores <3.
Moreover, no invasive candidiasis was observed in
patients with a “Candida score” = 3. Interestingly, we
also can underline that the performances of this score
are similar in medical and surgical patients. Surgical
patients exhibit more often a “Candida score” >3 than
medical patients, but the rate of invasive candidiasis is
similar in surgical and medical patients with a “Candida
score” >3.
Therapeutic decisions of intensivists in our group
could be discussed. Decision to initiate antifungal drugs
during this observational study was at the discretion of
each attending physician. Nevertheless, we observed a
relationship between initiation of antifungal agents and
value of the “Candida score.” Frequency of antifungal
empirical therapy were 2.3%, 27.6%, 41.2%, and 75% in
patients with scores equal to 2, 3, 4, and 5, respectively.
In our opinion, this is rather satisfying because most
patients with highly improbable invasive candidiasis did
not receive antifungal drugs, whereas early empirical
antifungal treatment was initiated in most patients who
would benefit from it. However, the fact that only a
quarter of patients with score = 3 received an empiric
antifungal treatment merits some comments. In our ser-
ies, all included patients exhibited severe sepsis or septic
s h o c ka n d ,t h e r e f o r e ,h a da“Candida score” always at
least equal to 2. Initiation of empirical antifungal treat-
ment to all patients with another risk factor (surgery or
total parenteral nutrition or multifocal Candida coloni-
zation) probably seemed to be excessive to most intensi-
vists of our group. The absence of invasive candidiasis,
among the 29 patients with a “Candida score” =3 ,r e t -
rospectively confirm the appropriateness of their
decision.
This study has numerous limitations. First, the num-
ber of included patients is low compared with the num-
ber of patients studied by Leon and his group [21,22].
The inclusion of patients with severe sepsis or septic
shock rather than all ICU admitted patients, and the
low number of ICU participating to this cohort study
explain this fact. Second, only five invasive candidiasis
and, among them, only one candidemia were observed
in this cohort. The low number of invasive candidiasis
can be explained, first, with some exclusion criteria such
as neutropenia, and, second, with the setting of the ICU;
Table 3 Severity scores and mortality, according to the value of “Candida score”
Candida score = 2
(n = 44)
Candida score = 3
(n = 29)
Candida score = 4
(n = 17)
Candida score = 5
(n = 4)
p
Mean SAPS ± SD 51.61 ± 16.79 49.72 ± 15.93 52.18 ± 21.84 52 ± 8.04 0.981
Mean SOFA score ± SD 8.8 ± 3.3 7.41 ± 3.27 8.59 ± 4.71 8.5 ± 1.73 0.583
Overall mortality 22 (50%) 11 (38%) 11 (64.7%) 2 (50%) 0.37
Mortality according to the initiation of an empiric antifungal treatment
Candida score = 2 Candida score = 3 Candida score = 4 Candida score = 5 p
Yes 1/1 3/8 4/7 2/3 0.59
No 21/43 8/21 7/10 0/1 0.3
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one in a university hospital. Third, in some patients, the
“Candida score” could not be calculated when sepsis or
shock occurred, because some mycological data were
lacking. However, this only reflects the shortcomings of
a real-life study and represents one limit to the practical
use of the score.
Conclusions
Our study confirms the clinical relevance of the “Can-
dida score” in patients with hospital-acquired severe
sepsis or septic shock. This score can differentiate
patients who would benefit from early antifungal treat-
ment from those for whom invasive candidiasis is highly
improbable.
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